What Is Claimed Is:

- 1. An isolated protein comprising an amino acid sequence selected from the group consisting of:
 - (a) amino acid residues 1 to 234 of SEQ ID NO:2;
 - (b) amino acid residues 2 to 234 of SEQ ID NO:2;
 - (c) amino acid residues 1 to 234 of SEQ ID NO:4; and
 - (d) amino acid residues 2 to 234 of SEQ ID NO:4.
- 2. The protein of claim 1, wherein the amino acid sequence is (a).
- 3. The protein of claim 1, wherein the amino acid sequence is (b).
- 4. The protein of claim 1, wherein the amino acid sequence is (c).
- 5. The protein of claim 1, wherein the amino acid sequence is (d).
- 6. The protein of claim 1 wherein the amino acid sequence further comprises a heterologous polypeptide.
- 7. The protein of claim 6 wherein the heterologous polypeptide is the Fc domain of immunoglobulin.
- 8. The protein of claim 1 wherein said protein is glycosylated.
- 9. The protein of claim 1 wherein said protein is fused to polyethylene glycol.

86

FOR EXAMINER'S REFERENCE ONLY DO NOT PUBLISH

- 10. An isolated protein produced by a method comprising:
 - (a) expressing the protein of claim 1 by a cell; and
 - (b) recovering the protein.
- 11. A composition comprising the protein of claim 1 and a carrier.
- 12. An isolated protein comprising an amino acid sequence selected from the group consisting of:
 - (a) the amino acid sequence of the full-length polypeptide encoded by the cDNA in ATCC Deposit No. 209005;
 - (b) the amino acid sequence of the full-length polypeptide, excluding the N-terminal methionine residue, encoded by the cDNA in ATCC Deposit No. 209005;
 - (c) the amino acid sequence of the full-length polypeptide encoded by the cDNA in ATCC Deposit No. 209006; and
 - (d) the amino acid sequence of the full-length polypeptide, excluding the N-terminal methionine residue, encoded by the cDNA in ATCC Deposit No. 209006.
- 13. The protein of claim 12, wherein the amino acid sequence is (a).
- 14. The protein of claim 12, wherein the amino acid sequence is (b).
- 15. The protein of claim 12, wherein the amino acid sequence is (c).
- 16. The protein of claim 12, wherein the amino acid sequence is (d).
- 17. The protein of claim 12 wherein the amino acid sequence further comprises a heterologous polypeptide.

87

FOR EXAMINER'S REFERENCE ONLY DO NOT PUBLISH

- 18. The protein of claim 17 wherein the heterologous polypeptide is the Fc domain of immunoglobulin.
- 19. The protein of claim 12 wherein said protein is glycosylated.
- 20. The protein of claim 12 wherein said protein is fused to polyethylene glycol.
- 21. An isolated protein produced by a method comprising:
 - (a) expressing the protein of claim 12 by a cell; and
 - (b) recovering the protein.
- 22. A composition comprising the protein of claim 12 and a carrier.
- 23. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
 - (a) at least 30 contiguous amino acid residues of SEQ ID NO:2;
 - (b) at least 50 contiguous amino acid residues of SEQ ID NO:2;
 - (c) at least 30 contiguous amino acid residues of SEQ ID NO:4; and
 - (d) at least 50 contiguous amino acid residues of SEQ ID NO:4.
- 24. The polypeptide of claim 23, wherein the amino acid sequence is (a).
- 25. The polypeptide of claim 23, wherein the amino acid sequence is (b).
- 26. The polypeptide of claim 23, wherein the amino acid sequence is (c).
- 27. The polypeptide of claim 23, wherein the amino acid sequence is (d).

- 28. The polypeptide of claim 23 wherein the polypeptide is fused to a heterologous polypeptide.
- 29. The polypeptide of claim 28 wherein the heterologous polypeptide is the Fc domain of immunoglobulin.
- 30. The polypeptide of claim 23 wherein said polypeptide is glycosylated.
- 31. The polypeptide of claim 23 wherein said polypeptide is fused to polyethylene glycol.
- 32. An isolated polypeptide produced by a method comprising:
 - (a) expressing the polypeptide of claim 23 by a cell; and
 - (b) recovering the polypeptide.
- 33. A composition comprising the polypeptide of claim 23 and a carrier.
- 34. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
 - (a) at least 30 contiguous amino acid residues encoded by the cDNA in ATCC Deposit No. 209005;
 - (b) at least 50 contiguous amino acid residues encoded by the cDNA in ATCC Deposit No. 209005;
 - (c) at least 30 contiguous amino acid residues encoded by the cDNA in ATCC Deposit No. 209006; and
 - (d) at least 50 contiguous amino acid residues encoded by the cDNA in ATCC Deposit No. 209006.
- 35. The polypeptide of claim 34, wherein the amino acid sequence is (a).

89

FOR EXAMINER'S REFERENCE ONLY DO NOT PUBLISH

- 36. The polypeptide of claim 34, wherein the amino acid sequence is (b).
- 37. The polypeptide of claim 34, wherein the amino acid sequence is (c).
- 38. The polypeptide of claim 34, wherein the amino acid sequence is (d).
- 39. The polypeptide of claim 34 wherein the polypeptide is fused to a heterologous polypeptide.
- 40. The polypeptide of claim 39 wherein the heterologous polypeptide is the Fc domain of immunoglobulin.
- 41. The polypeptide of claim 34 wherein said polypeptide is glycosylated.
- 42. The polypeptide of claim 34 wherein said polypeptide is fused to polyethylene glycol.
- 43. An isolated polypeptide produced by a method comprising:
 - (a) expressing the polypeptide of claim 34 by a cell; and
 - (b) recovering the polypeptide.
- 44. A composition comprising the polypeptide of claim 34 and a carrier.
- 45. An isolated human protein consisting of an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:
 - (a) amino acid residues 1 to 234 of SEQ ID NO:2; and
 - (b) amino acid residues 1 to 234 of SEQ ID NO:4.

- 46. The protein of claim 45, wherein the amino acid sequence is (a).
- 47. The protein of claim 45, wherein the amino acid sequence is (b).
- 48. The protein of claim 45 wherein the amino acid sequence further comprises a heterologous polypeptide.
- 49. The protein of claim 48 wherein the heterologous polypeptide is the Fc domain of immunoglobulin.
- 50. The protein of claim 45 wherein said protein is glycosylated.
- 51. The protein of claim 45 wherein said protein is fused to polyethylene glycol.
- 52. An isolated protein produced by a method comprising:
 - (a) expressing the protein of claim 45 by a cell; and
 - (b) recovering the protein.
- 53. A composition comprising the protein of claim 45 and a carrier.
- 54. An isolated human protein consisting of an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:
 - (a) the amino acid sequence of the full-length polypeptide encoded by the cDNA in ATCC Deposit No. 209005; and
 - (b) the amino acid sequence of the full-length polypeptide encoded by the cDNA in ATCC Deposit No. 209006.

- 55. The protein of claim 54, wherein the amino acid sequence is (a).
- 56. The protein of claim 54, wherein the amino acid sequence is (b).
- 57. The protein of claim 54 wherein the amino acid sequence further comprises a heterologous polypeptide.
- 58. The protein of claim 57 wherein the heterologous polypeptide is the Fc domain of immunoglobulin.
- 59. The protein of claim 54 wherein said protein is glycosylated.
- 60. The protein of claim 54 wherein said protein is fused to polyethylene glycol.
- 61. An isolated protein produced by a method comprising:
 - (a) expressing the protein of claim 54 by a cell; and
 - (b) recovering the protein.
- 62. A composition comprising the protein of claim 54 and a carrier.